- Home
- GLTO vs IVDA Comparison
GLTO vs IVDA Comparison
Compare GLTO & IVDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- IVDA
- Stock Information
- Founded
- GLTO 2011
- IVDA 2003
- Country
- GLTO Denmark
- IVDA United States
- Employees
- GLTO N/A
- IVDA N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- IVDA Computer Software: Prepackaged Software
- Sector
- GLTO Health Care
- IVDA Technology
- Exchange
- GLTO Nasdaq
- IVDA Nasdaq
- Market Cap
- GLTO 4.5M
- IVDA 4.3M
- IPO Year
- GLTO 2020
- IVDA N/A
- Fundamental
- Price
- GLTO $2.83
- IVDA $1.44
- Analyst Decision
- GLTO Buy
- IVDA
- Analyst Count
- GLTO 1
- IVDA 0
- Target Price
- GLTO $10.00
- IVDA N/A
- AVG Volume (30 Days)
- GLTO 248.1K
- IVDA 269.0K
- Earning Date
- GLTO 10-31-2025
- IVDA 11-13-2025
- Dividend Yield
- GLTO N/A
- IVDA N/A
- EPS Growth
- GLTO N/A
- IVDA N/A
- EPS
- GLTO N/A
- IVDA N/A
- Revenue
- GLTO N/A
- IVDA $7,142,302.00
- Revenue This Year
- GLTO N/A
- IVDA $340.48
- Revenue Next Year
- GLTO N/A
- IVDA N/A
- P/E Ratio
- GLTO N/A
- IVDA N/A
- Revenue Growth
- GLTO N/A
- IVDA 88.96
- 52 Week Low
- GLTO $2.01
- IVDA $1.27
- 52 Week High
- GLTO $14.56
- IVDA $8.05
- Technical
- Relative Strength Index (RSI)
- GLTO 39.82
- IVDA 36.16
- Support Level
- GLTO $2.45
- IVDA $1.36
- Resistance Level
- GLTO $3.99
- IVDA $1.62
- Average True Range (ATR)
- GLTO 0.30
- IVDA 0.11
- MACD
- GLTO -0.03
- IVDA 0.01
- Stochastic Oscillator
- GLTO 24.68
- IVDA 25.00
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About IVDA Iveda Solutions Inc.
Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).